scholarly journals Adiponectin improves coronary no-reflow injury by protecting the endothelium in rats with type 2 diabetes mellitus

2017 ◽  
Vol 37 (4) ◽  
Author(s):  
Xue Han ◽  
Ye Wu ◽  
Xin Liu ◽  
Lu Ma ◽  
Tingting Lv ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cell Adhesion ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Ischemia Reperfusion ◽  
No Reflow ◽  
Cell Adhesion Molecule 1

To determine the effect of adiponectin (APN) on the coronary no-reflow (NR) injury in rats with Type 2 diabetes mellitus (T2DM), 80 male Sprague–Dawley rats were fed with a high-sugar–high-fat diet to build a T2DM model. Rats received vehicle or APN in the last week and then were subjected to myocardial ischemia reperfusion (MI/R) injury. Endothelium-dependent vasorelaxation of the thoracic aorta was significantly decreased and serum levels of endothelin-1 (ET-1), intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) were noticably increased in T2DM rats compared with rats without T2DM. Serum APN was positively correlated with the endothelium-dependent vasorelaxation, but negatively correlated with the serum level of ET-1. Treatment with APN improved T2DM-induced endothelium-dependent vasorelaxation, recovered cardiac function, and decreased both NR size and the levels of ET-1, ICAM-1 and VCAM-1. Hypoadiponectinemia was associated with the aggravation of coronary NR in T2DM rats. APN could alleviate coronary NR injury in T2DM rats by protecting the endothelium and improving microcirculation.

scholarly journals Levels of soluble cell adhesion molecules in type 2 diabetes mellitus patients with macrovascular complications

2019 ◽  
Vol 48 (4) ◽  
pp. 030006051989385
Author(s):  
Gehan A Hegazy ◽  
Zuhier Awan ◽  
Enayat Hashem ◽  
Nabil Al-Ama ◽  
Asmaa Basha Abunaji
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cell Adhesion ◽  
Adhesion Molecules ◽  
Adhesion Molecule ◽  
Serum Levels ◽  
Macrovascular Complications ◽  
Soluble Adhesion Molecules

Objective Type 2 diabetes mellitus (T2DM) is a main risk factor for development of cardiovascular diseases (CVDs) and endothelial dysfunction. This study aimed to investigate serum levels of soluble vascular cell adhesion molecule 1 (sVCAM-1), intercellular adhesion molecule 1 (sICAM-1), and endothelium selectin (sE-selectin) in T2DM patients with macrovascular complications. Methods A cross-sectional study of 21 controls, 30 T2DM patients without CVDs, and 30 T2DM patients with CVDs was conducted. Serum levels of soluble adhesion molecules including sVCAM-1, sICAM-1, and sE-selectin were determined using ELISA. Results Serum levels of sVCAM-1, sICAM-1, and sE-selectin were higher in T2DM patients than in controls. Levels of serum sVCAM-1 were higher in T2DM patients with CVDs compared with T2DM patients without CVDs. In T2DM patients with CVDs, significant positive associations were observed between sVCAM-1, sICAM-1, and sE-selectin levels (r = 0.575, p = 0.001 and r = 0.378, p = 0.040). Conclusions Circulating levels of soluble adhesion molecules were elevated in T2DM patients, regardless of whether the patients had cardiovascular complications. Only sVCAM-1 was considered a useful marker for the prediction of CVDs in T2DM patients.

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

2011 ◽  
Vol 11 (6) ◽  
pp. 288-297
Author(s):  
Sabita S Soedamah-Muthu ◽  
Val Charlton-Menys ◽  
Weihang Bao ◽  
Casper Schalkwijk ◽  
Coen Da Stehouwer ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cell Adhesion ◽  
Adhesion Molecule ◽  
Tumour Necrosis ◽  
Cell Adhesion Molecule ◽  
Prior History ◽  
History Of ◽  
Cell Adhesion Molecule 1 ◽  
Necrosis Factor

We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)α, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether adhesion molecules were associated with incident CVD. Baseline and follow-up concentrations of TNFα, sVCAM-1 and sICAM-1 were measured in patients from the Collaborative AtoRvastatin Diabetes Study (CARDS). Patients had a mean age of 61 years (standard deviation = 8) and 70% were men. TNFα 2.20 pg/mL (1.82–2.86), sVCAM-1 865 ng/mL (729–1059) and sICAM-1 619 ng/mL (533–753) concentrations (median, interquartile range 25, 75%) were similar at baseline in atorvastatin (given values) and placebo groups and not significantly different at 2 years. The multivariable hazard ratios for the associations between sVCAM-1 and sICAM-1 (doubling the concentration) and CVD were, 0.82 (95% confidence interval (CI) 0.66–1.0) and 0.59 (95% CI 0.50–0.71), respectively. In conclusion atorvastatin had no significant effect on TNFα, sVCAM-1 or sICAM-1 levels in type 2 diabetic patients without a prior history of CVD compared with placebo. In addition, both sVCAM-1 and sICAM-1 concentrations were associated with a decreased risk of CVD.

Sign in / Sign up

Export Citation Format

Share Document